CAPR Investor Alert: Capricor Therapeutics, Inc. Securities Class Action Notice - Contact SueWallSt
Levi & Korsinsky LLP, through its SueWallSt brand, issued a solicitation notice for a securities class action against Capricor Therapeutics covering shareholders who purchased CAPR between December 17, 2025 and July 26, 2026; the lead plaintiff deadline is September 28, 2026. The release restates that CAPR fell from $19.70 to $4.19 — a roughly 78.7% decline with an alleged $15.08 per-share loss — following FDA briefing documents on the Phase 3 HOPE-3 trial of deramiocel.
Key figures
- Adcom vote
- 9-3 against efficacy
- Pdufa date
- August 22, 2026
- Class period
- December 17, 2025 - July 26, 2026
- Per share loss
- 15.08
- Drop jul27 2026
- $12.70 (64%)
- Drop jul30 2026
- $2.38 (36%)
- Price after decline
- 4.19
- Price before decline
- 19.7
- Total decline percent
- 78.7%
- Lead plaintiff deadline
- September 28, 2026
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.